J.HornD
Type 2 diabetes: principles of pathogenesis and therapy
Preclinical studies have demonstrated that GLP-1R agonists can reduce the accumulation of amyloid plaques, a hallmark of Alzheimer's disease, and improve synaptic function
Two 10-year case-control studies over very large samples of people with diabetes ( N = 360,205 and N = 73,869, respectively) equally observed no association between GLP-1RA use and incident depression 202,203
compounded tirzepatide is prepared for an individual patient by a 503A pharmacy and is not FDA-approved
A lawyer specializing in pharmaceutical litigation, particularly GLP-1 drugs personal injury cases, can evaluate your situation, explain your rights, and determine the best course of action